| Literature DB >> 30266660 |
Anne S Tsao1, O Wolf Lindwasser2, Alex A Adjei3, Prasad S Adusumilli4, Matthew L Beyers5, Gideon M Blumenthal6, Raphael Bueno7, Bryan M Burt8, Michele Carbone9, Suzanne E Dahlberg10, Marc de Perrot11, Dean A Fennell12, Joseph Friedberg13, Ritu R Gill14, Daniel R Gomez15, David H Harpole16, Raffit Hassan17, Mary Hesdorffer18, Fred R Hirsch19, Julija Hmeljak20, Hedy L Kindler21, Edward L Korn22, Geoffrey Liu23, Aaron S Mansfield3, Anna K Nowak24, Harvey I Pass25, Tobias Peikert26, Andreas Rimner27, Bruce W S Robinson28, Kenneth E Rosenzweig29, Valerie W Rusch4, Ravi Salgia30, Boris Sepesi31, Charles B Simone32, Rajeshwari Sridhara5, Peter Szlosarek33, Emanuela Taioli34, Ming-Sound Tsao35, Haining Yang8, Marjorie G Zauderer36, Shakun M Malik37.
Abstract
On March 28- 29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation convened the NCI-International Association for the Study of Lung Cancer- Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting in Bethesda, Maryland. The goal of the meeting was to bring together lead academicians, clinicians, scientists, and the U.S. Food and Drug Administration to focus on the development of clinical trials for patients in whom malignant pleural mesothelioma has been diagnosed. In light of the discovery of new cancer targets affecting the clinical development of novel agents and immunotherapies in malignant mesothelioma, the objective of this meeting was to assemble a consensus on at least two or three practice-changing multimodality clinical trials to be conducted through NCI's National Clinical Trials Network. CrownEntities:
Keywords: Clinical trials; Malignant mesothelioma; Multimodality therapy; Pleural; Targeted therapy
Mesh：
Year: 2018 PMID： 30266660 DOI： 10.1016/j.jtho.2018.08.2036
Source DB: PubMed Journal: J Thorac Oncol ISSN： 1556-0864 Impact factor: 15.609